The Preliminary Analysis of Sentinel Lymph Node Biopsy Guided by 99mTc-Rituximab in Patients with Breast Cancer.
Conclusions: Sentinel lymph node biopsy with 99mTc-Rituximab has high success rate and low false-negative rate. It is beneficial to the choice of individual treatment schedule. It can reduce unnecessary lymph node dissection and avoid sugery complication and has a high application value.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: XU, Y., ZHANG, Y., Chen, W. X., LIN, Z. Tags: Translational Image Guided Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Inflammatory Breast Cancer | Neoadjuvant Therapy | Nuclear Medicine | Pregnancy | Rituxan | SPECT | Statistics | Study | Women